BC
Brian N Cherry (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Atara Biotherapeutics, Inc. (ATRA). Across 1 priced purchase filing, the average 21-session return was -0.5% from execution and -0.5% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of ATRA (104,166 sh × $9.60, as filed), executed Sep 4. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-0.5%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-0.5%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1000K
shares × price, as filed
Last traded
Sep 4
Filed Sep 4
Median ADV $642K across their filed names
Open performance→Volume by month
Buys $1000K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ATRARecent filings
ATRAPURCHASE
Atara Biotherapeutics, Inc.
View filing →
$1000K104,166 sh × $9.60
Exec Sep 4
Filed Sep 4 · 6:20 PM ET